<DOC>
	<DOC>NCT02094443</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the pharmacodynamic (i.e. hepatitis C virus (HCV) viral load), pharmacokinetic and safety profiles between two treatment groups receiving different doses of DEB025 in combination with ribavirin (RBV) during the first 12 weeks treatment in chronic hepatitis C genotype (GT)-2 and GT-3 patients who had previously failed interferon therapy or were intolerant or unable to take interferon.</brief_summary>
	<brief_title>Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>1. Written informed consent must be obtained before any assessment is performed 2. Participants with HCV genotype 2 or 3 infection who have previously failed interferon therapy or are intolerant or unable to take interferon 3. Males or females aged â‰¥18 years 4. Diagnosed Chronic hepatitis C virus infection Exclusion criteria: 1. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 halflives of that medication before enrollment 2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes 3. Hepatitis B surface antigen (HBsAg) positive 4. Human immunodeficiency virus (HIV) positive Other protocoldefined inclusion/exclusion criteria apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chronic hepatitis C genotype 2</keyword>
	<keyword>Chronic hepatitis C genotype 3</keyword>
	<keyword>Cyclophilin inhibitor</keyword>
	<keyword>Interferon intolerant</keyword>
</DOC>